CN109414425A - 3-[2-丁基-1-(2-二乙基氨基-乙基)-1h-苯并咪唑-5-基]-n-羟基-丙烯酰胺的多晶型形式及其用途 - Google Patents

3-[2-丁基-1-(2-二乙基氨基-乙基)-1h-苯并咪唑-5-基]-n-羟基-丙烯酰胺的多晶型形式及其用途 Download PDF

Info

Publication number
CN109414425A
CN109414425A CN201780041511.XA CN201780041511A CN109414425A CN 109414425 A CN109414425 A CN 109414425A CN 201780041511 A CN201780041511 A CN 201780041511A CN 109414425 A CN109414425 A CN 109414425A
Authority
CN
China
Prior art keywords
base
ethyl
butyl
diethylamino
benzimidazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780041511.XA
Other languages
English (en)
Chinese (zh)
Inventor
大卫·邓肯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pathway Therapeutics Inc
Original Assignee
Pathway Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pathway Therapeutics Inc filed Critical Pathway Therapeutics Inc
Publication of CN109414425A publication Critical patent/CN109414425A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780041511.XA 2016-05-02 2017-05-01 3-[2-丁基-1-(2-二乙基氨基-乙基)-1h-苯并咪唑-5-基]-n-羟基-丙烯酰胺的多晶型形式及其用途 Pending CN109414425A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662330673P 2016-05-02 2016-05-02
US62/330,673 2016-05-02
PCT/US2017/030414 WO2017192451A1 (en) 2016-05-02 2017-05-01 Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ehtyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereof

Publications (1)

Publication Number Publication Date
CN109414425A true CN109414425A (zh) 2019-03-01

Family

ID=60203321

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780041511.XA Pending CN109414425A (zh) 2016-05-02 2017-05-01 3-[2-丁基-1-(2-二乙基氨基-乙基)-1h-苯并咪唑-5-基]-n-羟基-丙烯酰胺的多晶型形式及其用途

Country Status (20)

Country Link
US (2) US10626092B2 (https=)
EP (2) EP3452035B1 (https=)
JP (1) JP2019514905A (https=)
KR (1) KR20190005904A (https=)
CN (1) CN109414425A (https=)
AR (1) AR108257A1 (https=)
AU (1) AU2017261218A1 (https=)
BR (1) BR112018072439A2 (https=)
CA (1) CA3022011A1 (https=)
CL (1) CL2018003109A1 (https=)
CO (1) CO2018012941A2 (https=)
EA (1) EA201892341A1 (https=)
ES (1) ES2886495T3 (https=)
IL (1) IL262578A (https=)
MA (1) MA44880A (https=)
MX (1) MX382095B (https=)
PH (1) PH12018502296B1 (https=)
SG (1) SG11201809471UA (https=)
TW (1) TW201741286A (https=)
WO (1) WO2017192451A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018157742A1 (zh) * 2017-02-28 2018-09-07 苏州科睿思制药有限公司 Sb-939的盐的晶型及其制备方法和用途
EP3728205A1 (en) 2017-12-19 2020-10-28 Assia Chemical Industries Ltd Crystalline polymorphs of pracinostat and pracinostat salts
WO2019149262A1 (zh) * 2018-02-05 2019-08-08 苏州科睿思制药有限公司 Sb-939的晶型及其制备方法和用途
US20230159468A1 (en) * 2020-04-22 2023-05-25 Macfarlan Smith Limited Novel forms of pracinostat dihydrochloride

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008108741A1 (en) * 2007-03-07 2008-09-12 S*Bio Pte Ltd Combination of benzimidazole anti-cancer agent and a second anti-cancer agent
CN101287712A (zh) * 2005-09-08 2008-10-15 S*Bio私人有限公司 杂环化合物
US8143282B2 (en) * 2005-09-08 2012-03-27 S*Bio Pte Ltd. Heterocyclic compounds
US20150258068A1 (en) * 2012-10-30 2015-09-17 Mei Pharma, Inc. Combination therapies

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2291749A1 (fr) 1974-11-20 1976-06-18 Delalande Sa Nouveaux benzimidazoles acetiques, leur procede de preparation et leur application en therapeutique
JPH07508039A (ja) 1992-05-20 1995-09-07 メルク　エンド　カンパニー　インコーポレーテッド ４−アザステロイドのエステル誘導体
SE9804212D0 (sv) 1998-12-04 1998-12-04 Astra Pharma Prod Compounds
IL144214A0 (en) 1999-01-13 2002-05-23 Warner Lambert Co Benzoheterocycles and their use as mek inhibitors
EP1206260A4 (en) 1999-06-30 2002-10-30 Merck & Co Inc SRC-KINASE INHIBITING COMPOUNDS
WO2001000213A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
ES2208364T3 (es) 1999-07-16 2004-06-16 Warner-Lambert Company Llc Procedimiento para tratar dolor cronico usando inhibidores de mek.
PL352835A1 (en) 1999-07-16 2003-09-08 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
GB9919558D0 (en) 1999-08-18 1999-10-20 Hoechst Schering Agrevo Gmbh Fungicidal compounds
EP1748046A3 (en) 1999-11-23 2007-08-22 Methylgene, Inc. Inhibitors of histone deacetylase
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
NZ514403A (en) 1999-12-27 2002-10-25 Japan Tobacco Inc Fused-ring compounds and use thereof as drugs
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
EP1332131A2 (en) 2000-11-07 2003-08-06 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
WO2003000682A1 (en) 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
AU2003209060A1 (en) 2002-02-07 2003-09-02 Axys Pharmaceuticals, Inc. Assay for acytyltransferase or deacetylase activity
KR100984595B1 (ko) 2002-03-13 2010-09-30 어레이 바이오파마 인크. Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체
EP1482944A4 (en) 2002-03-13 2006-04-19 Array Biopharma Inc NZ ALKYL BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS
CA2484261A1 (en) 2002-04-16 2003-10-23 Teijin Limited Piperidine derivatives having ccr3 antagonism
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
WO2004078682A2 (en) 2003-03-05 2004-09-16 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
US7381825B2 (en) 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2005028447A1 (en) 2003-09-22 2005-03-31 S*Bio Pte Ltd Benzimidazole derivates: preparation and pharmaceutical applications
US20050137234A1 (en) 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
US20050159470A1 (en) 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
WO2006101456A1 (en) 2005-03-21 2006-09-28 S*Bio Pte Ltd Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101287712A (zh) * 2005-09-08 2008-10-15 S*Bio私人有限公司 杂环化合物
US8143282B2 (en) * 2005-09-08 2012-03-27 S*Bio Pte Ltd. Heterocyclic compounds
WO2008108741A1 (en) * 2007-03-07 2008-09-12 S*Bio Pte Ltd Combination of benzimidazole anti-cancer agent and a second anti-cancer agent
US20150258068A1 (en) * 2012-10-30 2015-09-17 Mei Pharma, Inc. Combination therapies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CAYMAN CHEMICAL COMPANY: "《Cayman Chemical》", 1 March 2015 *
JAYARAMAN ET AL: "Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone", 《DRUG METABOLISM & DISPOSITION》 *
STEPHEN BYRN, ET AL: "Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations", 《PHARMACEUTICAL RESEARCH》 *
傅晓沧: "药物的多晶型", 《医药工业》 *

Also Published As

Publication number Publication date
EP3452035A4 (en) 2019-09-25
EP3452035A1 (en) 2019-03-13
PH12018502296B1 (en) 2022-04-06
SG11201809471UA (en) 2018-11-29
AR108257A1 (es) 2018-08-01
CA3022011A1 (en) 2017-11-09
CL2018003109A1 (es) 2019-04-26
AU2017261218A1 (en) 2018-11-29
EP3939966A1 (en) 2022-01-19
PH12018502296A1 (en) 2019-07-08
EA201892341A1 (ru) 2019-05-31
WO2017192451A1 (en) 2017-11-09
CO2018012941A2 (es) 2018-12-28
JP2019514905A (ja) 2019-06-06
MA44880A (fr) 2021-03-17
MX382095B (es) 2025-03-13
KR20190005904A (ko) 2019-01-16
MX2018013349A (es) 2019-02-20
IL262578A (en) 2018-12-31
ES2886495T3 (es) 2021-12-20
EP3452035B1 (en) 2021-07-07
TW201741286A (zh) 2017-12-01
US20200317621A1 (en) 2020-10-08
US20190152923A1 (en) 2019-05-23
US10626092B2 (en) 2020-04-21
BR112018072439A2 (pt) 2019-02-19

Similar Documents

Publication Publication Date Title
WO2022237815A1 (en) Novel forms of Compound I and use thereof
ES2750676T5 (en) Crystalline dihydrochloride hydrate salt of omecamtiv mecarbil and process for its preparation
JP2022140559A (ja) Ｒａｄ１９０１－２ｈｃｌの多形性形態
CN110483486B (zh) 一种奥西替尼酮咯酸盐晶型及其制备方法
WO2011095059A1 (zh) 达沙替尼多晶型物及其制备方法和药物组合物
CN109414425A (zh) 3-[2-丁基-1-(2-二乙基氨基-乙基)-1h-苯并咪唑-5-基]-n-羟基-丙烯酰胺的多晶型形式及其用途
TWI675839B (zh) 一種ｊａｋ激酶抑制劑的硫酸氫鹽的結晶形式及其製備方法
AU2016258388A1 (en) Novel crystal of uracil compound
CN102086195A (zh) 达沙替尼多晶型物及其制备方法和药用组合物
US20250115565A1 (en) Solid crystalline forms of helicase-primase inhibitors and process of preparation thereof
US20250263391A1 (en) Crystalline form of tegavivint, method of preparation, and use thereof
JP2024518429A (ja) ４－［５－［（３ｓ）－３－アミノピロリジン－１－カルボニル］－２－［２－フルオロ－４－（２－ヒドロキシ－２－エチルプロピル）フェニル］フェニル］－２－フルオロ－ベンゾニトリルの塩の固体形態
BR122020016731B1 (pt) Forma f de tartarato cristalino de 5-(2,4-diamino-pirimidin-5-iloxi)-4-isopropil-2-metoxi- benzenossulfonamida, bem como sua composição farmacêutica e uso
US10053452B2 (en) Crystalline forms of N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine salts and uses thereof
CN112119073A (zh) 阿贝西尼的固态形式、其用途和制备
CN119350344B (zh) 巴瑞替尼邻苯二甲酸盐晶型及其制备
WO2016101867A1 (zh) 萘普替尼对甲苯磺酸盐的α晶型及制备方法和含有其的药物组合物
CN116751204A (zh) 一种巴瑞克替尼-没食子酸共晶及其制备方法和应用
TW202413369A (zh) 呋喃嘧啶化合物酸加成鹽之晶形及藥物組成物
CN113372331A (zh) 一种奥希替尼一水合物新晶型
WO2017152858A1 (zh) 色瑞替尼的晶型及其制备方法
CN108117570A (zh) 一种替诺福韦艾拉酚胺半富马酸盐的结晶及其制备方法
TW202502340A (zh) 菸酸酯類化合物的無定型物、多晶型物及其製備方法和用途
CN106188017B (zh) R构型4-(取代苯胺基)喹唑啉衍生物及其制备方法和用途
BR112017015828B1 (pt) Compostos derivados de pirazolo[3,4-d]pirimidina, composição farmacêutica e combinação compreendendo ditos compostos e uso dos mesmos para o tratamento de leishmaniose

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190301

WD01 Invention patent application deemed withdrawn after publication